Showing 2301-2310 of 6373 results for "".
Special Report: Dermatology Industry Responds to Inequities in Care
https://practicaldermatology.com/topics/skin-of-color/special-report-dermatology-industry-responds-to-inequities-in-care/23765/Currents
https://practicaldermatology.com/topics/practice-management/currents/21098/Bugs in DermatologyCase Report: First Reported Case of Facial Rash After Dupilumab Therapy; Call for Abstracts
https://practicaldermatology.com/youngmd-connect/resident-resource-center/case-report-first-reported-case-of-facial-rash-after-dupilumab-therapy-call-for-abstracts/20499/Micromanagement: Microparticles Enhance Outcomes of Energy-based Acne Care
https://practicaldermatology.com/topics/general-topics/micromanagement-microparticles-enhance-outcomes-of-energy-based-acne-care/20384/With recent FDA-clearance, microparticles are available to support Nd:YAG based treatment of inflammatory acne.New Drugs in Psoriasis
https://practicaldermatology.com/topics/psoriasis/new-drugs-in-psoriasis/20933/The last two years have seen a number of new drugs approved to treat psoriasis—from targeted biologics to new topicals.Triple Threat
https://practicaldermatology.com/topics/general-topics/triple-threat/20629/In defense of the Aron Regimen for resistant atopic dermatitis.Currents: Eczema
https://practicaldermatology.com/topics/atopic-dermatitis/currents-eczema/23371/Currents: Year In Focus
https://practicaldermatology.com/topics/skin-cancer-photoprotection/currents-year-in-focus/23167/To Sell or Not To Sell: Strategic Options and Realizing Value
https://practicaldermatology.com/topics/practice-management/to-sell-or-not-to-sell-strategic-options-and-realizing-value/20418/Is this the right time to make a change? Here's what you need to know.Get Ready: The Biosimilars Are Here
https://practicaldermatology.com/topics/psoriasis/get-ready-the-biosimilars-are-here/20662/Recent developments mean that biosimilars are finally hitting the US market.